Abstract
Substance P, an 11-amino acid neuropeptide, has an important role in modulating pain transmission through neurokinin 1 and 2 receptors. Substance P and other tachykinins may also play a role in the pathogenesis of inflammatory diseases. In this study we present the results concerning the metabolism of the substance P analogue [111In-DTPA-Arg1]-substance P in man, as well as the visualization of the thymus in patients with immune-mediated diseases. Twelve selected patients were investigated, comprising five with inflammatory bowel disease, one with ophthalmic Graves' disease, one with sclerosing cholangitis, one with Sjögren's syndrome, one with rheumatoid arthritis, one with systemic lupus erythematosus and two with myasthenia gravis. During and after intravenous administration of 150-250 MBq (2.5–5.0 μg) [111In-DTPA-Arg1]-substance P, blood pressure, heart rate and oxygen saturation were monitored. Radioactivity was measured in blood, urine and faeces during the 48 h after injection. Planar and single-photon emission tomographic images were obtained 4 and 24 h after injection. After administration of [111In-DTPA-Arg1]-substance P, a transient flush was observed in all patients. Degradation of [111In-DTPA-Arg1]-substance P started in the first minutes after administration, resulting in a half-life of 10 min for the total plasma radioactivity, and of 4 min for the intact radiopharmaceutical, as identified with high-performance liquid chromatography. Urinary excretion accounted for >95% of the radioactivity within 24 h post injection, and up to 0.05% was found in the faeces up to 60 h. In all patients uptake of radioactivity was found in the areolae mammae (in women), liver, spleen, kidneys and urinary bladder. In eight patients a high uptake of [111In-DTPA-Arg1]-substance P was observed in the thymus. We conclude that, despite its short half-life, [111In-DTPA-Arg1]-substance P, a new radio-pharmaceutical, can be used to visualize the thymus. This may contribute to the investigation of the role of thymus in immune-mediated diseases. In addition, inflammatory sites in various diseases could be visualized.
Similar content being viewed by others
References
Chang MM, Leeman SE. Isolation of a sialogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 1970; 245: 4784–4790.
Walsh DA, Salmon M, Wharton J, Mapp PI, Polak JM. Autoradiographic localisation and characterisation of substance P binding sites in rat knees. Regul Pept 1993; 46: 189–192.
Walsh DA, Mapp PI, Salmon M, Rutherford RAD, Kidd BL, Revell PA, Balke DR, Polak JM. Localisation and characterisation of substance P binding to human synovium in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 313–317.
Mantyh PW, Gates TS, Zimmerman RP, Welton ML, Passaro RP, Vigna SR, Maggio JE, Kruger L, Mantyh PW. Receptor binding sites for substance P, but not substance K, or neuromidin K, are expressed in high concentrations by arterioles, venules, and lymph nodes in surgical specimens from patients with ulcerative colitis and Crohn's disease. Proc Natl Acad Sci USA 1988; 85: 3235–3239.
Mantyh WM. Substance P and the inflammatory and immune response. Ann NY Acad Sci 1991; 632: 263–271.
Walsh DA, Salmon M, Mapp PI, Wharton J, Garrett N, Blake DR, Polak JM. Microvascular substance P binding to normal and inflamed rat and human synovium. J Pharmacol Exp Ther 1993; 267: 951–960.
Joyce TJ, Yood RA, Carraway RE. Quantitation of substance P and its metabolites in plasma and synovial fluid from patients with arthritis. J Clin Endocrinol Metab 1993; 77: 632–637.
Foreman JC, Jordan CC. Histamine release and vascular changes induced by neuropeptides. Agent Actions 1983; 13: 105–116.
Ruff MR. Wahl SM, Pert CB. Substance P receptor mediated chemotaxis of human monocytes. Peptides 1985; 6: 107–111.
Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ. Substance P recognition by a subset of human T lymphocytes. J Clin Invest 1984; 74: 1532–1539.
Stanisz AM, Befus D, Bienenstock J. Differential effects of vasoactive peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 1986; 136: 152–156.
Rosai J, Levine GD. Tumors of the thymus. In: Atlas of tumor pathology, second series, fascicle 13. Washington DC: Armed Forces Institute of Pathology; 1976; 26–33; 133-137.
Levine GD, Rosai J. Thymie hyperplasia and neoplasia: a review of concepts. Human Pathol 1978; 9: 495–515.
Hoffmann WJ, Moller P, Otto HE Thymic hyperplasia. II. Lymphoreticular hyperplasia of the thymus. An immunohistologic study. Klin Wochenschr 1987; 65: 53–60.
Tridente G. Immunopathology of the human thymus. Semin Hematol 1985; 22: 56–57.
Piantelli M, Maggiano N, Larocca LM, Ricci R, Ranelletti FO, Lauriola L, Capelli A. Neuropeptide-immunoreactive cells in the human thymus. Braira Behav Immun 1990; 4: 189–197.
Lorton D, Bellinger DL, Felten SY, Felten DL. Substance P innervation of the rat thymus. Peptides 1990; 11: 1269–1275.
Shigematsu K, Saavedra JM, Kurihara M. Specific substance P binding sites in rat thymus and spleen: in vitro autoradiographie study. Regul Pept 1986; 16: 147–156.
Breeman WAP, Van Hagen PM, Visser-Wisselaar HA, van der Pluijm ME, Koper JW, Setyono-Han B, Bakker WH, Kwekke-boom DJ, Hazenberg MP, Lamberts SWJ, Krenning EP. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-lll-DTPA-Arg1]substance P. J Nucl Med 1996; 37: 108–117.
Breeman WAP, Holland LJ, van der Pluijm M, Koetsveld PM, deJong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SWJ, Krenning EP. A new radiolabelled somatostatin analogue [111ln-DTPA-d-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-d-Phe1]octreotide. Eur J Nucl Med 1994; 21: 328–335.
Reubi JC, Mazzuccheli L, Laissue J. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 1994; 106: 951–959.
Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance P receptors in human primary neoplasms: tumoural and vascular localisation. Int J Cancer 1995; 61: 786–792.
Coiro V Capretti L, Volpi R, Davoli C, Marcato A, Cavazzini U, Caffarri G, Rossi G, Chiodera P. Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate. Neuroendocrinology 1992; 56: 459–463.
Schaffalitzky De Muckadel OB, Aggestrup S, Stentoft P. Flushing and plasma substance P concentration during infusion of synthetic substance P in normal men. Scand J Gastroenterol 1986; 21: 498–502.
Mussap CJ, Gerargthy DP, Burcher E. Tachykinin receptors: a radioligand binding perspective. Review. J Neurochem 1993; 60: 1987–2009.
Ericsson A, Geenen V Robert F, Legros JJ. Expression of preprotachykinin-A and neuropeptide-Y messenger RNA in the thymus. Mol Endocrinol 1990; 4: 1211–1214.
Vincent A, Newton-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 1983; 33: 1276–1282.
Kuks JBM, Oosterhuis HIGH, Limburg PC, The TH. Antiacetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991; 4: 197–211.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Hagen, P.M., Breeman, W.A.P., Reubi, J.C. et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23, 1508–1513 (1996). https://doi.org/10.1007/BF01254476
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01254476